Atlas of Genetics and Cytogenetics in Oncology and Haematology

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

t(11;14)(q13;q32) IGH/CCND1

Written1998-05Jean-Loup Huret
Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France

(Note : for Links provided by Atlas : click)


Atlas_Id 2021
Note t(11;14) is mainly found in mantle cell lymphoma, but also in B-prolymphocytic leukaemia, in plasma cell leukaemia, in splenic lymphoma with villous lymphocytes, in chronic lymphocytic leukaemia, and in multiple myeloma, herein briefly described; all these diseases involve a B-lineage lymphocyte.
  t(11;14)(q13;q32) Top: G- banding - Courtesy Diane H. Norback, Eric B. Johnson, Sara Morrison-Delap Cytogenetics at theWaisman Center and R- banding: Third row - Editor; last row and FISH - Courtesy Hossein Mossafa.

Clinics and Pathology

Disease mantle cell lymphoma
Phenotype / cell stem origin B-cell non Hodgkin lymphoma of the low to intermediate grade
Epidemiology annual incidence 5/106; median age: 65 yrs
Clinics advanced disease
Prognosis median survival: 3 to 4 yrs

Disease B-prolymphocytic leukaemia
Phenotype / cell stem origin chronic lymphoproliferative disorder affecting mature B-cells
Epidemiology rare disease; median age 70 yrs
Clinics patients often present with advanced stage disease
Prognosis median survival: 3 yrs

Disease plasma cell leukaemia
Phenotype / cell stem origin proliferation involving plasma cells
Epidemiology rare disorder
Prognosis median survival is less than a yr

Disease splenic lymphoma with villous lymphocytes
Phenotype / cell stem origin chronic B-cell lymphoproliferation
Epidemiology rare disorder; median age: 70 yrs
Clinics relatively benign clinical course
Prognosis 80% 5-yr survival

Disease chronic lymphocytic leukaemia
Phenotype / cell stem origin chronic B-cell lymphoproliferation
Epidemiology annual incidence 30/106; median age: 60-80 yrs
Clinics often a slow evolutive disease
Prognosis highly variable according to the staging: from staging A: survival not reduced compared to age matched population, to staging C: median survival of 2 yrs

Disease multiple myeloma
Phenotype / cell stem origin malignant plasma cell proliferation (terminally differenciated B-cell)
Epidemiology annual incidence: 30/106; median age: 60 yrs
Prognosis median survival: 3 yrs.


Cytogenetics Morphological t(11;14) has earlier been thought to be the hallmark of the mantle cell lymphoma; actually, the frequency of t(11;14) is: 50-70% in mantle cell lymphoma, 10-20% in B-prolymphocytic leukaemia, in plasma cell leukaemia, and in splenic lymphoma with villous lymphocytes, and 2-5% in chronic lymphocytic leukaemia, and in multiple myeloma.
Cytogenetics Molecular in particular interphase cytogenetics, are relevant in these diseases with an usually low mitotic index
Additional anomalies sole anomaly in only 10% of cases; part of a complex karyotype in 2/3 of cases; numerous recurrent anomalies found conjointly (which is the primary?), particularly: +3, +7, del(9p), +18, + mar, found in about 10% of cases each; other: del(1p), del(6q), del(7q), -8, +12, del(13q), del(17p)
Variants three way complex t(11;14; Var) exist and showed that the crucial event lies on der(14)

Genes involved and Proteins

Gene NameCCND1 (B-cell leukemia/lymphoma 1)
Location 11q13.3
Dna / Rna 5 exons
Protein encodes the cyclin D1; role in the cell cycle control: G1 progression and G1/S transition
Gene NameIGH (Immunoglobulin Heavy)
Location 14q32.33

Result of the chromosomal anomaly

Hybrid gene
Description 5' BCL1 translocated on chromosome 14 near JH (junctions genes of IgH) and C in 3'; the breakpoint in BCL1 is in MTC (major translocation cluster), centromeric to the gene (in 5'), in 80% of cases, or dispersed in mTC1, 2, or 3 in 5'of the gene or in the 3' untranslated region of exon 5.
Fusion Protein
Description no fusion protein, but promoter exchange; the immunoglobulin gene enhancer stimulates the expression of BCL1
Oncogenesis overexpression of BCL1 accelerates passage through the G1 phase.


Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors.
Bosch F, López-Guillermo A, Campo E, Ribera JM, Conde E, Piris MA, Vallespí T, Woessner S, Montserrat E
Cancer. 1998 ; 82 (3) : 567-575.
PMID 9452276
Genes and chromosomes in chronic B-cell leukemia.
Crossen PE
Cancer genetics and cytogenetics. 1997 ; 94 (1) : 44-51.
PMID 9078290
Cytogenetics of lymphomas: a brief review of its theoretical and practical significance.
Donner LR
Cancer genetics and cytogenetics. 1997 ; 94 (1) : 20-26.
PMID 9078287
Cytogenetics and molecular genetics in multiple myeloma.
Feinman R, Sawyer J, Hardin J, Tricot G
Hematology/oncology clinics of North America. 1997 ; 11 (1) : 1-25.
PMID 9081201
Prognostic factors in chronic lymphocytic leukemia.
Hallek M, Kuhn-Hallek I, Emmerich B
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 1997 ; 11 Suppl 2 : S4-13.
PMID 9178831
Overexpression of the PRAD1 oncogene in a patient with prolymphocytic leukemia with t(11;14)(q13;q32).
Kobayashi H, Kitano K, Saito H, Aoki K, Narita A, Terada N, Sonoyama M, Uchimaru K, Machii T, Motokura T
Cancer genetics and cytogenetics. 1995 ; 84 (1) : 69-72.
PMID 7497446
Mantle cell lymphoma: diagnostic criteria, clinical aspects and therapeutic problems.
Meusers P, Hense J, Brittinger G
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 1997 ; 11 Suppl 2 : S60-S64.
PMID 9178843
The ultrastructure of mantle cell lymphoma and other B-cell disorders with translocation t(11;14)(q13;q32).
Resnitzky P, Matutes E, Hedges M, Morilla R, Brito-Babapulle V, Khokhar T, Catovsky D
British journal of haematology. 1996 ; 94 (2) : 352-361.
PMID 8759896
Rearrangement and overexpression of the BCL-1/PRAD-1 gene in intermediate lymphocytic lymphomas and in t(11q13)-bearing leukemias.
Rimokh R, Berger F, Delsol G, Charrin C, Berthéas MF, Ffrench M, Garoscio M, Felman P, Coiffier B, Bryon PA
Blood. 1993 ; 81 (11) : 3063-3067.
PMID 8499640
Overexpression of PRAD1/cyclin D1 in plasma cell leukemia with t(11;14)(q13;q32).
Shimazaki C, Goto H, Araki S, Tatsumi T, Takahashi R, Hirai H, Kikuta T, Yamagata N, Ashihara E, Inaba T, Fujita N, Suzuki R, Nakagawa M
International journal of hematology. 1997 ; 66 (1) : 111-115.
PMID 9220667


This paper should be referenced as such :
Huret, JL
Atlas Genet Cytogenet Oncol Haematol. 1998;2(4):129-131.
Free journal version : [ pdf ]   [ DOI ]
On line version :

Translocations implicated (Data extracted from papers in the Atlas)

 t(11;14)(q13;q32) IGH/CCND1

External links

IGH (14q32.33) CCND1 (11q13.3)

Mitelman databaset(11;14)(q13;q32) [Case List]    t(11;14)(q13;q32) [Transloc-MCList] IGH/CCND1 [Fusion-MCList]
arrayMap (UZH-SIB Zurich)[select an item]
Mitelman databaseIGH/CCND1 [MCList]  IGH (14q32.33) CCND1 (11q13.3)
REVIEW articlesautomatic search in PubMed
Last year articlesautomatic search in PubMed
All articlesautomatic search in PubMed

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Wed Nov 13 22:14:37 CET 2019

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us